Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

Patrick Joseph O'Shea; Vineeth Tatineni; Yasmeen Rauf; Xuefei Jia; Erin Sennett Murphy; Samuel T. Chao; John H. Suh; David M. Peereboom; Manmeet Singh Ahluwalia

doi:10.1200/JCO.2021.39.15_SUPPL.2030

Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

Patrick Joseph O'Shea
, Vineeth Tatineni
, Yasmeen Rauf
, Xuefei Jia
, Erin Sennett Murphy
, Samuel T. Chao
, John H. Suh
, David M. Peereboom
, Manmeet Singh Ahluwalia

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2030
State	Published - May 20 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2021.39.15_SUPPL.2030License: Unspecified

Cite this

@article{a3f106556a4c4cbfb91b269a317992d7,

title = "Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.",

author = "O'Shea, \{Patrick Joseph\} and Vineeth Tatineni and Yasmeen Rauf and Xuefei Jia and Murphy, \{Erin Sennett\} and Chao, \{Samuel T.\} and Suh, \{John H.\} and Peereboom, \{David M.\} and Ahluwalia, \{Manmeet Singh\}",

note = "2030 Background: Renal cancer is the fourth most common cause of metastatic tumors to the brain. Tyrosine kinase inhibitors (TKIs) targeting VEGFR and other receptors, such as sunitinib, pazopanib, etc., have been used as first line for renal cell carcinoma brain metastasis (RCCBM).",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15\_SUPPL.2030",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

AU - O'Shea, Patrick Joseph

AU - Tatineni, Vineeth

AU - Rauf, Yasmeen

AU - Jia, Xuefei

AU - Murphy, Erin Sennett

AU - Chao, Samuel T.

AU - Suh, John H.

AU - Peereboom, David M.

AU - Ahluwalia, Manmeet Singh

N1 - 2030 Background: Renal cancer is the fourth most common cause of metastatic tumors to the brain. Tyrosine kinase inhibitors (TKIs) targeting VEGFR and other receptors, such as sunitinib, pazopanib, etc., have been used as first line for renal cell carcinoma brain metastasis (RCCBM).

PY - 2021/5/20

Y1 - 2021/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2030

U2 - 10.1200/JCO.2021.39.15_SUPPL.2030

DO - 10.1200/JCO.2021.39.15_SUPPL.2030

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

Disciplines

Access to Document

Other files and links

Cite this